Monitor upcoming quarterly filings or pipeline updates for signs of strategic shifts under new leadership. The addition of experienced board members may enhance capital allocation and development strategy, but no immediate catalysts are evident.
Price Chart
Executive Summary
Damora Therapeutics appointed Jennifer Jarrett as CEO and President, effective March 30, 2026, alongside key additions to its Board of Directors, including biotech leaders Dr. Cameron Turtle and Mike Landsittel. Peter Harwin was named Chairman of the Board, replacing departing directors who contributed to the recent Damora-Galecto transaction.
Key Facts
- Jennifer Jarrett appointed President and CEO of Damora Therapeutics, effective March 30, 2026.
- Jarrett brings nearly 30 years of leadership experience in biotech, tech, and finance, including prior roles at Arcus Biosciences, Uber, and Medivation.
- Dr. Cameron Turtle and Mike Landsittel appointed to Damora’s Board of Directors.
- Peter Harwin named Chairman of the Board; replaces departing directors Dr. Carl Goldfischer, Dr. Jayson Dallas, and Amit Munshi.
- No financial figures, guidance changes, or operational updates were disclosed in the announcement.
Financial Impact
No immediate financial impact disclosed; leadership transition may influence strategic direction over time.
Risk Factors
- Leadership transitions carry execution risk, especially in early-stage biotechs where strategy is closely tied to executive vision.
- Departure of prior board members involved in the Galecto transaction may signal a shift in strategic focus.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260313 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $20.26 | awaiting T+20 | — | $21.26 (+4.96%) |
Sep 28, 2026 28d ago | Insider Buy | $20.75 $21.26 | ▲ +2.46% | ▲ +2.49% | $21.26 (+2.46%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $28.10 | ▼ −8.56% | ▼ −6.81% | $21.26 (−30.82%) |
Aug 10, 2026 11w ago | Press Release | $30.36 $26.27 | ▲ +13.47% | ▲ +12.41% | $21.26 (+29.97%) |
Jul 20, 2026 14w ago | 8-K | $32.99 $31.80 | ▼ −3.61% | ▼ −6.17% | $21.26 (−35.56%) |
Apr 20, 2026 27w ago | 8-K | $26.82 $24.90 | ▼ −7.16% | ▼ −12.07% | $21.26 (−20.73%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $26.82 | ▲ +16.36% | ▲ +8.94% | $21.26 (−7.77%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $26.43 | ▲ +45.70% | ▲ +36.38% | $21.26 (+17.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers